Abstract The hippocampus plays an important role in memory, mood, and spatial navigation. In the dentate gyrus of the adult hippocampus, in the subgranular zone (SGZ), new cells are generated, which differentiate and mature into new neurons. Cisplatin, a highly effective antineoplastic drug with nephrotoxic and ototoxic side effects, induces apoptosis and suppresses neurogenesis in the hippocampus leading to memory impairment. Previous studies have shown that the antioxidant D-methionine protects against cisplatin-induced ototoxicity and nephrotoxicity suggesting that it might also prevent neurogenesis from being suppressed by cisplatin treatment. To test this hypothesis, rats were treated with cisplatin, D-methionine, cisplatin plus D-methionine, or saline (controls). Seven days after treatment, the rats were sacrificed, and hippocampal sections immunolabeled for doublecortin (DCX) to identify neuronal precursor cells and maturing neurons in the SGZ. Cisplatin significantly reduced the number of DCX-labeled cells (*80 %) relative to controls. In contrast, DCX cell counts in rats treated with D-methionine prior to cisplatin were similar to controls. The treatment with D-methionine alone did not affect the number of DCX cells. These results indicate that D-methionine prevents the dramatic cisplatin-induced decrease of neurogenesis.
Introduction
Hippocampal neurogenesis (Altman and Chorover 1963; Eriksson et al. 1998; Gage 2000) is believed to play an important role in long-term memory (Snyder et al. 2005) , whereas neuronal precursor cells in the subgranular zone (SGZ) in the dentate gyrus give rise to new neurons which migrate to the granular cell layer. Treatment with chemotherapeutic agents causes impairment in cognitive functions, memory, and attention, a phenomenon commonly known as ''chemo-brain'' or ''chemo-fog'' (Staat and Segatore 2005) . Cisplatin is one of the most commonly used platinum-based chemotherapeutic drugs and has been shown to damage the central nervous system and negatively affect the rate of neurogenesis (Dietrich et al. 2006; Duffner 2006) . Importantly, cisplatin was found to be more toxic to the neuronal precursor cells and oligodendrocytes than it was to tumor cells.
One mechanism by which cisplatin causes damage is by oxidative stress and depletion of antioxidant enzymes (Chen et al. 2007 ). Thus, treatment with antioxidants may help in rebalancing endogenous antioxidants to normal levels and prevent tissue damage. Antioxidants have been shown to protect the inner ear against cisplatin-induced ototoxicity by reducing oxidative stress (Vogt 1995; Campbell et al. 2003; Rybak and Whitworth 2005) . The antioxidant D-methionine, the dextro-isomer of the amino acid L-methionine, was found to protect normal tissues, but not tumor cells against radiation and cisplatin-induced toxicity (Campbell et al. 2003; Vuyyuri et al. 2008 ). D-methionine, which protects against cisplatin-induced weight loss, also provided significant protection against cisplatin-induced damage in the inner ear (Campbell et al. 1996) .
In this study, we tested the hypothesis that D-methionine would prevent cisplatin from suppressing hippocampal neurogenesis. Doublecortin (DCX), a microtubule-associated protein, is expressed in hippocampal neuronal precursor cells and maturing neurons (Brown et al. 2003; Rao and Shetty 2004; Couillard-Despres et al. 2005) and therefore used as a marker of neurogenesis in the hippocampus.
Methods
Fourteen adult male Sprague-Dawley rats (SASCO, Charles River Laboratories, International, Inc., Wilmington, MA, USA), three months of age, were used for this study. All animal procedures were carried out in accordance with the ethical standards in the NIH guidelines for use and care of laboratory animals and approved by the University of Buffalo Institutional Animal Care and Use Committee (protocol HER05080Y).
The anticancer drug cisplatin (12 mg/kg; SigmaAldrich, Inc., St. Louis, MO, USA) was administered intraperitoneally under isoflurane anesthesia (4 % induction, 1.5-2 % maintenance; Webster Veterinary Supply Inc., Sterling, MA, USA) at a concentration of 1 mg/ml in 0.9 % sterile saline and at a speed of 0.15 ml/min. This dose, consistent with our previous studies (Manohar et al. 2014) , resulted in strong, reliable effects on the neuronal precursor population in rats and was within the range of cisplatin doses typically used in cytotoxicity studies (Cloven et al. 2000; Campbell et al. 2003; Maimaitiyiming et al. 2013 ). D-methionine (Sigma-Aldrich) (300 mg/kg) diluted in 0.9 % saline at a concentration 30 mg/ml was administered intraperitoneally. Three sham controls received 0.9 % saline instead of cisplatin. Three rats received only cisplatin. Another three rats received D-methionine 30 min prior to treatment with cisplatin. Injection of D-methionine prior to cisplatin treatment ensured that it was already taken up before cisplatin was applied. Finally, three rats were treated only with D-methionine. All 12 rats were sacrificed on day 7 posttreatment. For prescreening, two further rats were treated with cisplatin alone and sacrificed at 2 or 21 days later. All rats were hydrated with 0.9 % saline (once with 5 ml s.c. on the day of the cisplatin injection and twice a day with 10 ml/kg from post-treatment day 1-7). Among the rats treated with only cisplatin, 50 % survived, while all the rats in the other groups survived (sham controls, cisplatin plus D-methionine, D-methionine).
On the day of sacrifice, rats received a lethal dose of sodium pentobarbital and were transcardially perfused with 0.1 M phosphate buffered saline (PBS, 0.1 M, pH 7.4; Sigma-Aldrich) for 5 min to remove red blood cells, and then with 10 % phosphate buffered formalin (Fischer Scientific, Pittsburgh, PA, USA; with a formaldehyde concentration of 4 %) for fixation at room temperature for 15 min. Brains were taken out of the skulls and post-fixated in formalin for one more week. Brain tissue containing the left or right hippocampus was immersed in 30 % sucrose (Sigma-Aldrich) in 0.1 M PBS pH 7.4 (Sigma-Aldrich) overnight at 4°C for cryoprotection. On the following day, the brain tissue was cut on a cryostat into 30-lm-thick sections at -30°C. Tissue sections were collected in 0.1 M PBS, pH 7.4 and washed for 30 min at room temperature. Between every successive incubation steps described below, sections were washed in PBS, pH 7.4 for 15 min, and the buffer was changed three times. For deactivation of endogenous peroxidase, sections were treated with 0.05 % H 2 O 2 (Fischer Scientific) in distilled water for 30 min. Next, the sections were pretreated with blocking solution containing 10 % normal horse serum (Vector Laboratories, Burlingame, CA, USA) and 0.05 % Triton X-100 (Fischer Scientific) in 0.1 M PBS, pH 7.4 (''PBS-Triton'') for 30 min. Incubation with the primary antibody against doublecortin (DCX; polyclonal; made in goat; sc-8066; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA; 2 lg/ml) in PBS-Triton with 1.0 % normal horse serum lasted for 2 h at room temperature. The specificity of this polyclonal DCX-antibody was previously shown by Brown et al. (2003) with a western blot study ruling out cross-reactions. Subsequent incubation with biotinylated secondary antibody (anti-goat IgG, Vector Laboratories; 5 ll/ml), in PBS-Triton with 1.5 % normal horse serum, was done for 60 min at room temperature. For the ABC reaction, sections were treated with avidin and biotin (Elite-ABC kit, Vector Laboratories; 20 ll of reagent A and reagent B respectively/ml) in PBS-Triton for 60 min at room temperature. After washing in PBS, sections were washed in 0.1 M Tris Buffer (Trizma-base, Sigma Aldrich), pH 7.2, for 15 min. Staining reaction using 0.05 % DAB (3 0 3 0 diaminobenzidine tetrahydrochloride) with 0.3 % nickel ammonium sulfate and 0.0015 % H 2 O 2 in Tris-buffer (Trizma-base, SigmaAldrich) was performed which resulted in a dark brown color. Subsequently, sections were washed in Tris-buffer once then in PBS at least three times, mounted on gelatincoated slides (Superfrost plus; Fisher Scientific) and dried overnight. The sections were dehydrated in increasing alcohol, cleared in xylene, and sealed using DPX (Fisher Scientific).
To determine antibody specificity on fixed tissue sections, preadsorption procedure was performed. The immunizing peptide (sc-8066 P, Santa Cruz, 1:100) was incubated with a 1:500 dilution of the DCX antibody in blocking solution (1,5 % NHS, 1 % BSA in PBS-Triton) for 30 min at room temperature. Hippocampus sections were treated with the standard immunostaining procedure described above, just with the preadsorped DCX antibody instead.
Cell profile counts of DCX immunopositive cells were done at 400 9 magnification using an Axisoscope microscope (Carl Zeiss MicroImaging, Inc., Thornwood, NY, USA). While profile counts do not deliver absolute numbers without careful correction, they are sufficient and reliable for detecting relative differences between groups, particularly if the effect size is large as in the current study (Guillery and Herrup 1997) . In our study, there were none or only minimal changes of DCX cell body size after treatment compared with controls. DCX-positive cell profiles were counted in a total of nine sections per rat distributed along the caudal-rostral axis of the hippocampus (three random sections from the rostral end where the SGZ has a horizontal orientation, another three from the middle region where the SGZ has a diagonal orientation and extends ventrally, and finally three sections from the most caudal region where most of the SGZ is oriented vertically from dorsal to ventral). Criteria for counting DCX-positive cells in the hippocampus have been described previously (Kraus et al. 2010) , specifically the presence of the nucleus or cell morphology (shape and size) with its cytoplasm homogeneously stained and clearly darker than its surroundings. Number of cells per millimeter was calculated by dividing DCX profile counts by the length of the SGZ (Kraus et al. 2010) , in order to correct for length differences due to cutting angle. Cell numbers/mm were then normalized to controls and presented as mean ± standard error of mean (SEM). The results were analyzed using Graphpad Prism (Version 5.01; GraphPad Software Inc., La Jolla, CA, USA), and statistical comparisons were done by the One-way ANOVA and Tukey's Multiple Comparison Test. Significance level was set to P B 0.05. Grayscale images were taken using a digital camera (SPOT Insight; Diagnostic Instruments, Inc., Sterling Heights, MI, USA) and processed using imaging software (SPOT Software, version 4.6). Figures were assembled using Adobe Photoshop 5.5 (Adobe Systems, Inc., San Jose, CA, USA).
Results
Immunostaining of the rat hippocampus visualized DCXpositive cell bodies along the SGZ in the dentate gyrus (Fig. 1a, b) . Preadsorption of the DCX antibody resulted in unstained sections (Fig. 1c, d) , verifying DCX-antibody specificity on fixed tissue sections. Figure 2 shows the effect of cisplatin on the DCX-positive neuronal precursor cells at different time points after treatment. In controls, the hippocampus shows a large number of DCX-positive cells. The cell bodies were arranged in a line along the SGZ. Two days after cisplatin treatment, we saw a slight reduction of the number of cell bodies compared with the controls. Seven days after treatment, a very large reduction was observed. After 21 days, the number of DCX cells had almost recovered back to the control level. Based on these observations, the protective properties of D-methionine were investigated on rats surviving for 7 days after cisplatin treatment. For quantification, we counted the numbers of DCXlabeled cells in the control group and the three experimental groups at 7 days post-treatment (Fig. 4) . The numbers of DCX-labeled cells were divided by the length of the SGZ; then normalized to the average in cell number controls, which was set to 1.0. The normalized average cell number 7 days after cisplatin treatment was 0.22 ± 0.015 (SEM), a reduction of almost 80 % compared with controls. This reduction was highly significant (One-way ANOVA, F = 27.77, df = 3, P \ 0.0001, Tukey post hoc comparison, P \ 0.001). In contrast, when D-methionine was administered along with cisplatin, the cell density was 0.8 ± 0.070 (SEM), significantly larger than that in rats treated with only cisplatin (Tukey post hoc comparison, P \ 0.01) while not being significantly different from controls or from animals treated only with D-methionine (Tukey post hoc analyses, P [ 0.05). When D-methionine was administered alone, the average cell density was 0.95 ± 0.099 (SEM) and not significantly different from controls (Tukey post hoc analysis, P [ 0.05).
Discussion
Cisplatin caused a massive reduction in the number of DCX-labeled cells in the dentate gyrus of the adult rat hippocampus compared with controls one week after treatment, consistent with previous observations (Dietrich Neurotox Res (2015 ) 27:199-204 201 et al. 2006 . This large decrease in neurogenesis would presumably impair hippocampal-related functions in these rats as reported in other studies (Shabani et al. 2012) as well as in patients undergoing chemotherapy who have reported impaired cognition and memory (Kaasa et al. 1988; Troy et al. 2000) . The reduced number of DCX cells in the SGZ has been linked to apoptosis-mediated cell death. Dietrich and co-workers observed a strong increase of TUNEL staining in the mouse hippocampus after treatment with cisplatin and other anticancer drugs, where neuronal precursor cells were far more vulnerable to cisplatin toxicity than mature neurons or neuroepithelial stem cells in vitro as well as in vivo (Dietrich et al. 2006) . Consistent with these morphological observations, Manohar et al. (2014) observed a significant up-regulation of pro-apoptotic genes Bik, Bid, Bok, Trp53p2, and Card6 2 days after cisplatin injection at the same dose as used in this study. An alternative explanation for the reduced DCX immunoreactivity in SGZ may be down-regulation of this protein in surviving cells; however, we are unaware of any studies that have documented such a change of expression. DCX is expressed in neuronal precursor cells as well as in maturing neurons, but is down-regulated during maturation and is absent in mature functional neurons (Brown et al. 2003; Rao and Shetty 2004; Couillard-Despres et al. 2005) . Therefore, the cisplatin-induced reduction of DCXpositive cells is indicative of reduced neurogenesis due to the death of neuronal precursor cells or maturing neurons, to the decreased proliferation of surviving precursor cells, or the failure of newborn cells to differentiate and mature into neural precursors. Earlier studies have shown that cisplatin reduces the number of hippocampal cells labeled with BrdU (Dietrich et al. 2006) or the cell division marker Ki67 (Manohar et al. 2014) , demonstrating a decreased rate of cell proliferation consistent with the reduced neurogenesis caused by cisplatin.
Rats treated with D-methionine plus cisplatin showed a significant increase in the number of DCX-labeled cells compared with cisplatin-treated rats. This may be due to the antioxidant property of D-methionine which reduces oxidative stress by binding free radicals, thereby reducing cell death (Vogt 1995) . In addition, D-methionine increases the production of mitochondrial reduced glutathione (GSH) which acts as an antioxidant thereby reducing oxidative Seven days after cisplatin treatment b, the number of cell bodies (arrow heads) was significantly reduced compared with controls (a). When treated with D-methionine before cisplatin (c), the number of cell bodies remained similar to controls. Scale bar 100 lm Fig. 4 Relative numbers of DCX cells in controls, cisplatin (Cis), cisplatin plus D-methionine (Cis ? D-met), and D-methionine (D-met) 7 days after treatment: Numbers were normalized to the control group which was set to 1.0. Rats treated with only cisplatin showed a large and significant reduction in cell density compared with controls and to animals treated with only D-methionine. D-methionine administered 30 min prior to cisplatin kept the number of DCX-positive cells comparable with the controls and with animals treated with only D-methionine, while it was significantly larger than that in animals treated with cisplatin. There were no significant differences between controls, animals treated with cisplatin plus D-methionine, and animals treated with only D-methionine Neurotox Res (2015) 27:199-204 203 stress-induced apoptosis (Campbell et al. 2003; Vuyyuri et al. 2008) . Alternatively, D-methionine may partially chelate cisplatin and reduce the concentration of unbound cisplatin in blood or tissues. In that case, the protective properties of D-methionine may be due to lower levels of systemic cisplatin rather than its antioxidant properties, thereby hindering the therapeutic properties of cisplatin (Ekborn et al. 2002) . However, this is unlikely to be a major factor because D-methionine has been shown to protect against cisplatin toxicity without significantly lowering the antitumor effectiveness (Jones and Basinger 1989; Cloven et al. 2000; Campbell et al. 2003) . The underlying reasons for such a selective protection of nontumor cells may be that nontumor cells have a different methionine metabolism from that of tumor cells (Campbell et al. 1996) . Cisplatin reduces the mitochondrial membrane potential thereby causing cell death (Maimaitiyiming et al. 2013) , while D-methionine mitigates the loss of mitochondrial membrane potential selectively in nontumor cells but not in tumor cells (Vuyyuri et al. 2008) , thereby selectively protecting nontumor cells.
In conclusion, D-methionine may be a promising drug for reducing the central and peripheral neurotoxic effects of cisplatin treatment, without reducing the antitumor effectiveness of cisplatin.
